The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved October 1998

Specific Treatments:


Therapeutic Areas

General Information

Treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy.

Side Effects

The adverse effects of Camptosar, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.

Other potential side effects include diarrhea, neutropenia among others.